Results 11 to 20 of about 1,140,223 (331)

STEAP3 Affects Ferroptosis and Progression of Renal Cell Carcinoma Through the p53/xCT Pathway

Technology in Cancer Research & Treatment, 2022
Renal cell carcinoma is particularly sensitive to ferroptosis, an iron-dependent non-apoptotic form of cell death. This mechanism does not require activation of caspase or the participation of other apoptotic effector molecules (such as BAX or BAK), nor ...
Cheng Lin Ye MS, Yang Du MD, Xi Yu MD, Zhi Yuan Chen MD, Lei Wang MD, Yong Fa Zheng MD, Xiu Heng Liu MD   +6 more
doaj   +2 more sources

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS In this phase 3 trial, we randomly assigned (
R. Motzer, B. Alekseev, S. Rha, C. Porta, M. Eto, T. Powles, V. Grünwald, Thomas E. Hutson, E. Kopyltsov, M. Méndez-Vidal, V. Kozlov, A. Alyasova, Sung-Hoo Hong, A. Kapoor, Teresa Alonso Gordoa, J. Merchan, E. Winquist, P. Maroto, J. Goh, Miso Kim, H. Gurney, V. Patel, A. Peer, G. Procopio, T. Takagi, B. Melichar, F. Rolland, U. de Giorgi, Shirley S. Wong, J. Bedke, M. Schmidinger, C. Dutcus, Alan D. Smith, L. Dutta, K. Mody, R. Perini, D. Xing, T. Choueiri   +37 more
semanticscholar   +1 more source

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.
T. Choueiri, T. Powles, M. Burotto, B. Escudier, M. Bourlon, B. Żurawski, V. O. Oyervides Juarez, J. Hsieh, U. Basso, A. Shah, C. Suarez, A. Hamzaj, J. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, Juan P Feregrino, J. Zolnierek, D. Pook, E. Kessler, Y. Tomita, R. Mizuno, J. Bedke, Joshua Zhang, M. Maurer, B. Simsek, F. Ejzykowicz, G. Schwab, A. Apolo, R. Motzer   +30 more
semanticscholar   +1 more source

Clear Cell Renal Cell Carcinoma: From Biology to Treatment

Cancers, 2023
Simple Summary Over the past two decades, biological discoveries have transformed the treatment strategies for renal cell carcinoma. These advances have led to the development of agents targeting pro-angiogenic pathways and the immunogenicity of renal ...
Adam M. Kase, D. George, Sundhar Ramalingam   +2 more
semanticscholar   +1 more source

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Network Boston, 2022
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of ...
N. Dizman, L. Meza, P. Bergerot, Marice B. Alcantara, T. Dorff, Y. Lyou, P. Frankel, Yujie Cui, Valerie Mira, M. Llamas, J. Hsu, Z. Zengin, N. Salgia, S. Salgia, J. Malhotra, N. Chawla, A. Chehrazi-Raffle, R. Muddasani, J. Gillece, L. Reining, Jeff Trent, Motomichi Takahashi, K. Oka, S. Higashi, M. Kortylewski, S. Highlander, S. Pal   +26 more
semanticscholar   +1 more source

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer, 2022
Conditional survival estimates provide critical prognostic information for patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional survival outcomes were assessed in CheckMate 214 (ClinicalTrials.gov identifier NCT02231749 ...
R. Motzer, D. McDermott, B. Escudier, M. Burotto, T. Choueiri, H. Hammers, P. Barthélémy, E. Plimack, C. Porta, S. George, T. Powles, F. Donskov, H. Gurney, C. Kollmannsberger, M. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B. Rini, M. McHenry, Chung-Wei Lee, Jennifer McCarthy, F. Ejzykowicz, N. Tannir   +24 more
semanticscholar   +1 more source

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

New England Journal of Medicine, 2015
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma.
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Y. Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, Padmanee Sharma   +26 more
semanticscholar   +1 more source

Case Report: Bilateral Renal Cell Carcinoma With Different Histological and Morphological Features, Clear Cell and Cystic Thyroid-Like Follicular Subtype

Frontiers in Oncology, 2021
Thyroid-like follicular renal cell carcinoma is a rare subtype of renal cell carcinoma that has only been recently recognized, as most cases involve a solid tumor in one kidney.
Jinsong Ni, Ni Cui, Yanfang Wang, Jixuan Liu   +3 more
doaj   +1 more source

Current trends in renal cell carcinoma

Journal of Medical and Scientific Research, 2014
Kidney cancer is one of the most lethal urological malignancies and surgery was the only treatment of modality a decade ago. Open radical nephrectomy was the procedure of choice for long time for all malignant masses.
Bhardwaj, Gopichand
doaj   +1 more source

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

New England Journal of Medicine, 2019
BACKGROUND The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal‐cell carcinoma.
B. Rini, E. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. McDermott, J. Bedke, S. Tartas, Yen‐Hwa Chang, S. Tamada, Qiong Shou, R. Perini, Mei Chen, M. Atkins, T. Powles   +26 more
semanticscholar   +1 more source